KTVZ: Walden presses insurers on rising insulin prices
Washington,
December 9, 2019
by KTVZ news sources
Rep. Greg Walden (R-OR), Republican Leader of the Energy and Commerce Committee and Rep. Michael Burgess (TX) are pressing top insurance companies for answers as to their role in the rising cost of insulin. In letters last week to Anthem, Blue Cross Blue Shield, CVS Health, Cigna Corporation, Kaiser Permanente and UnitedHealth Group, Walden and Burgess requested information on the relationship between insulin's list price and its negotiated price and the impact this negotiation process has on patients. “We are continuing to investigate the rising costs of health care across numerous services and products, including, but not limited to, spending on hospitals, physicians, and prescription drugs. As part of this work, we have focused on the increasing price of insulin for patients with diabetes,” Walden and Burgess wrote. In addition to the letter, Walden introduced the Lower Costs, More Cures Act, bipartisan legislation to lower costs at the drug counter for patients and seniors, including provisions specifically designed to make insulin more affordable. Although the list price of many insulin products significantly increased over the past decade, the net price received by manufacturers for many of these insulin products stayed the same or decreased over the same period. Click here to read the letters. Published here. |
Latest from twitter
Get the most up to date news from me on Twitter.